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Objectives. To determine the outcome of surgical intervention in patients with HIV associated vascular disease.
Design. Prospective clinical survey.
Materials and methods. Routine voluntary testing for HIV/AIDS was performed in patients who presented to our unit
with peripheral vascular disease. One hundred and nine patients (5.7%) were prospectively identified over a 5-year period
(2001e2006).
Results. 24 patients presented with aneurysmal disease whilst occlusive disease was present in 66 patients. There was not
much difference between patients with aneurysmal disease and patients with occlusive disease as to age, CD4 count and
other risk factors for vascular disease. The peri-operative mortality for aneurysmal disease was 10.6% versus 3.6% for oc-
clusive disease (p¼ 0.264). Long-term mortality was significantly worse (p¼ 0.049) for patients with aneurysmal dis-
ease. The results of revascularization in occlusive disease were poor with a limb salvage rate of 31.6%. There was no
significant difference in CD4 T-cell counts between primary amputation and revascularization groups (p¼ 0.058).
Conclusion. Patients with aneurysmal disease have a high peri-operative and long-term mortality and it appears that sur-
gical intervention should be reserved for life-threatening aneurysms only. Patients with occlusive disease have a better sur-
vival rate but limb salvage is poor. Primary amputation may be preferable to bypass surgery in patients with critical limb
ischaemia.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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South Africa has one of the most rapidly growing HIV
epidemics in the world1,2 with an estimated 5.4e5.6
million HIV-positive people (UNAIDS/WHO AIDS
December 2006).
There is a well documented relationship between
vascular disease and HIV infection.3e5 These patients
may present with occlusive disease, aneurysms, spon-
taneous arterio-venous fistula or the complications of
hypercoagulability. They may also, however, present
with the normal spectrum of vascular disease such
as atherosclerosis or trauma where HIV positivity is
an incidental finding. The aim of our study is to de-
scribe our experience with vascular surgery in HIV re-
lated vascular disease.6
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In January 2002 we started with a programme of rou-
tine voluntary testing for HIV/AIDS. Informed con-
sent was obtained in over 90% of all admissions.
Comprehensive screening for risk factors for athero-
sclerosis was carried out.
One hundred and nine patients were prospectively
identified over a 5-year period with follow-up data
available for 82% of patients. Patients who presented
with vascular emergencies were managed regardless
of their HIV status because this information was not
available at the time of presentation. As no specific
guidelines were available at the time, we based our
elective management on immune status, taking the
CD4 T-lymphocyte count into consideration. When
the CD4 T-cell count exceeded 500, patients were
managed according to standard vascular protocols
appropriate for sero-negative patients. If the CD4
T-cell count was between 200 and 500, a conservative
alternative to surgery was applied where possible. If
surgery was unavoidable, however, we opted forar Surgery. Published by Elsevier Ltd. All rights reserved.
391Surgical Intervention for HIV Related Vascular Diseasea less invasive procedure, e.g. extra-anatomic bypass
procedures such as axillo-femoral or femoro-femoral
bypasses were used rather than the more invasive
aorta-bifemoral bypass. In patients with established
AIDS (CD4 T-cell count< 200), palliative treatment
was administered unless critical limb ischaemia ne-
cessitated primary amputation or surgery meant sav-
ing a life. Standard surgical techniques were used and
no patients received endovascular treatment. Highly
active antiretroviral therapy (HAART) in state hospi-
tals became available in 2003, but was very slow to
reach effective numbers and none of our patients
were on active treatment.
Results
We tested for HIV in 1905 patients whom presented to
our unit with vascular disease. 109 Patients tested
HIV positive (5.7%). Patients that were HIV negative
had a very similar pattern of vascular disease as the
rest of the Western world. Patient demographics are
summarised in Table 1.
Aneurysmal disease was present in 22% (24 pa-
tients) and occlusive disease in 61% of our patients
(66 patients). Trauma accounted for 16 patients and
3 had spontaneous AV-fistulae.
Aneurysms were often multiple and in unusual
anatomical locations. Sixteen patients had multiple
aneurysms (Fig. 1). A young 30-year-old black man
presented with a total of 101 small saccular aneurysms
spread throughout his vascular system. A 46-year-old
black male presented with multiple aneurysms in both
internal and external iliac arteries, the right superficial
femoral artery (SFA) and fibular artery, and a massive
aneurysm in the left SFA. A 35-year-old black woman
presented with two saccular aneurysms of her supe-
rior mesenteric artery. A 45-year-old black male pre-
sented with eight aneurysms distributed in the distal
aorta, iliac, posterior tibial, subclavian and carotid
arteries. The femoral (Fig. 2) and carotid arteries
(Fig. 3) were most commonly involved.
Occlusive disease was mostly diffuse with a fibro-
obliterative appearance. There were long-segment oc-
clusions with poor distal run-off which are generally
not amenable to bypass surgery.
Table 1. Patient demographics (n[ 109)
Race Black 99 (90.8%)
White 4 (3.7%)
Mixed 4 (3.7%)
Asian 2 (1.8%)
Gender Male 88 (80.7%)
Female 21 (19.3%)
Age Age (mean) 40 yearsThe treatment employed is summarised in Table 2.
There was a failure rate of >75% for bypass sur-
gery, i.e. axillo-bifemoral, femoro-femoral and fem-
oro-popliteal procedures. Patients who underwent
thrombectomy also had disappointing outcomes. Pri-
mary amputations were done in 18 patients with
a high percentage of local sepsis. They were treated
on an outpatient basis and most healed within 3
months. Mean length of hospital stay in patients
with primary amputation was shorter than in patients
with failed bypass surgery and secondary amputation
(7 vs. 21 days). Further analysis of patients with lower
limb ischemia (aorta-iliac and femoro-popliteal distri-
bution) is summarized in Table 3.
There was not much difference between aneurys-
mal and occlusive disease according to age: (mean
39.3 vs. 40.7 years); CD4 T-cell count: (mean 323.2
(79e916) vs. 300.2 (15e926)) and other risk factors
for vascular disease. The peri-operative mortality
was 10.6% for aneurysmal disease and 3.6% for occlu-
sive disease. This did not reach statistical significance
( p¼ 0.264; Fisher’s exact test). Long-term mortality
was significantly worse ( p¼ 0.049; Log-rank test) for
patients with aneurysmal disease (Fig. 4 and Table 4).
Due to the skewness of CD4 T-cell count data, geo-
metric means and 95% confidence intervals are re-
ported as descriptive statistics. Comparisons were
done using analysis of variance for ranks and neither
primary amputation versus revascularization patients
( p¼ 0.058), nor secondary amputation versus limb
salvage from the revascularization group of patients
( p¼ 0.151) differed significantly. The CD4 T-cell count
also did not differ significantly between survivors and
non-survivors ( p¼ 0.227; Student’s two-sample t-test).
Twenty-eight patients had a CD4 count of <200.
Ten of these were still alive at the time of writing
with follow-up ranging from 12e48months (a survival
of up to 4 years without HAART), five were healthy
at follow-up of less than a year, seven died within
a year and six were lost to follow-up.
Discussion
HIV-associated vascular disease is a specific disease
entity which differs from atherosclerotic disease in
various aspects.
HIV positive patients are younger with an average
age of 40 years in comparison to 55e747 years in
patients with atherosclerotic disease. There is also
a lower incidence of the typical risk factors:
 Smoking: Although the incidence of cigarette
smoking was the same as in the atherosclerotic
Eur J Vasc Endovasc Surg Vol 34, October 2007
392 K. Botes and J. Van MarleFig. 1. 31-year old black patient with multiple saccular aneurysms.population, fewer cigarettes were smoked per day:
average of 5e10 cigarettes per day;
 Hypercholesterolaemia: 2% vs. 65%;7
 Diabetes mellitus: 2% vs. 18%;8
 Hypertension: 21% vs. 35e55%.9
HIV-related aneurysms have several histological
features distinguishing them from degenerative and
infective aneurysms. The principal feature is occlu-
sion of the vasa vasorum by an inflammatory cellinfiltrate, usually a leucocytoclastic vasculitis with
proliferation of slit-like vascular channels within the
adventitia. Weakening of the vessel wall due to the ar-
teritic process usually results in the formation of sac-
cular type aneurysms.10,11
Du Pont’s first report on aneurysms associated
with HIV was followed by many publications dealing
with this issue.5,12e14 HIV-associated aneurysms are
typically multiple and often occur in atypical loca-
tions with a predilection for the carotid andFig. 2. 28-year old black female with femoral aneurysm.
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393Surgical Intervention for HIV Related Vascular DiseaseFig. 3. 28-year old female with carotid aneurysm.superficial femoral arteries.15,16 Defining the role
played by HIV itself is complicated by the diverse op-
portunistic infections known to be associated with
vasculitic syndromes such as Epstein Barr, hepatitis
and cytomegalovirus. Some aneurysms are associated
with an infective agent, but cultures from our patients
were negative.
The results from our 5-year prospective study show
an increase in young patients presenting with ad-
vanced limb ischemia (rest pain, ulceration or gan-
grene). Our patients mainly presented with multilevel
occlusive disease. It is of a fibro-obliterative nature
and is seldom amenable to bypass surgery due to
inadequate run-off. Compared to patients with athero-
sclerotic disease, the results obtained in patients with
HIV-associated occlusive disease were much worse.
These patients have characteristic angiogram find-
ings of long-segment occlusions, pristine vessels prox-
imally and poor or absent distal run-off. Chetty and
Nair10 proposed that occlusive disease occurs second-
ary to the same leucocytoclastic vasculitis of the vasa
vasorum that causes large-vessel aneurysmal disease,
i.e. bipolar clinical expressions of the same pathologi-
cal process. This is not dissimilar to other arteritic
syndromes such as Takayasu’s and Behcet’s disease,
where occlusive and aneurysmal forms of the disease
occur with identical histopathological features. All
these clinical presentations may be due to the direct
and indirect effects on endothelial cells.
Although the precise pathogenesis of HIV-1 associ-
ated vascular disease is not clear, there have been
advances in the understanding of the biochemistryand cell biology of these changes.17 This is based on
biological and molecular activation of endothelial
cells (EC) in HIV-1 infection.
The direct effect on EC behaviour is selective im-
pairment in storage and/or excretion of molecules
such as endothelin-1 and Von Willebrand factor. The
indirect effect on EC behaviour involves trans-acting
transcription factor (Tat), a transcriptional activator
of viral expression produced early after infection,
which is essential for virus replication. During acute
infection of T-cells by HIV, trans-acting transcription
factor is released from the cells and activates a pro-
inflammatory and angiogenic programme. Trans-acting
transcription factor may compete with fibroblast
growth factor (FGF) for binding to heparin sulphate
proteoglycans of the cell surface and extracellular
matrix and thereby activate EC (Tat angiogenic effect).
Additionally trans-acting transcription factor binds
to and activates the tyrosine kinase receptor encoded
by vascular endothelial growth factor (VEGF) in EC
and Kaposi’s cells which induce vascular leakage
and stimulate proliferation of EC.17e19
Various factors influence the operative outcome of
surgery in HIV-positive patients,20 including immune
status (CD4 T-cell count), opportunistic infections,
WBC count, hematocrit, nutritional state (decreased
albumin) and type of operation (emergency vs. elec-
tive; clean vs. contaminated).
The US government classifies AIDS using two crite-
ria, namely theT-cell count andahistory ofAIDS-defin-
ing disease. Using the CD4 T-cell count as a parameter,
patients are classified asymptomatic (500 cells/mL),
Eur J Vasc Endovasc Surg Vol 34, October 2007
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AIDS (<200 cells/mL). Savoiz et al.,21,22 Yii et al.,23 and
Consten et al.24 showed that overall postoperative com-
plications (mostly infection) with lower CD4 T-cell
counts was as high as 39%. With CD4 T-cell counts
above 500 the morbidity was 6%, which is comparable
to that of HIV-negative patients.
Table 2. Treatment of 109 Patients
 Aneurysmal disease 24
B Abdominal Aorta 3
- Aorta-bifemoral graft 1
- Aorta tube graft 1
- Non-surgical management 1
B Thoraco-abdominal 3
- Non-surgical management 3
B Femoral artery 9
- SFA: Autologous vein interposition 4
- SFA: Fem-pop/AKA 1
- SFA: Repairedþ Fem-fem 1
- SFAþ renal/Died before ø 1
- SFA: Ligated 1
- CFA: Prosthetic interposition 1
B Popliteal artery 1
- Bilateral autologous interposition 1
B Superior mesenteric artery 1
B Carotid artery 4
- Ligated and excised 2
- Repaired with prosthesis 2
B Refused Rx (multiple locations) 3
 Occlusive disease 66
B Aorta-bifemoral bypass 3
B Femoro-femoral bypass 5
- 2 Amputation< 6 months 3
B Axillo-bifemoral bypass 5
- Removed due to graft sepsis 3
B Femoro-popliteal bypass 12
- 2 Amputation< 6 months 10
B Primary amputations 18
- Above-knee (AKA) 14
- Below-knee (BKA) 2
- Hip disarticulation 1
- Forearm 1
B Thrombectomy with fasciotomy 9
- Above-knee amputations 6
- Lost to follow-up 3
B Lumbar sympathectomy 4
- Lost to follow-up 3
B Non-surgical management 10
 Trauma 16 Spontaneous AV-fistula 3
Table 3. Analysis of patients with lower limb ischemia
Aorta-iliac Femoro-popliteal
(n) 23 42
Primary amputation 6 (26%) 12 (29%)
Surgical bypass procedure 12 (52%) 26 (62%)
Non-surgical (Cx) 5 (22%) 4 (9.5%)
Late amputation 7 (41%) 15 (50%)
Peri-operative mortality 1 (5.5%) 1 (2.6%)
Long-term mortality 9 (50%) 9 (26%)
Limb salvage 5 (42%) 7 (27%)
Lost to follow-up 5 (22%) 7 (17%)
Eur J Vasc Endovasc Surg Vol 34, October 2007To our surprise a significant number of our patients
with a CD4 T-cell count of <200 survived longer than
1.3 years without HAART (average¼ 2 years), which
is in contradiction with current literature.25 Patients
should therefore be individualised and not categor-
ised according to the CD4 T-cell count as the only
predictor.
The basic principles of vascular surgery also apply
to HIV-positive patients. Autogenous vein is the pre-
ferred conduit, and if vein is not available, PTFE or
polyester grafts are used. The commercially available
silver-impregnated grafts are used if there is a high
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Fig. 4. Kaplan-Meier survival estimates, by group. Aneurys-
mal survival significantly worse than occlusive survival
( p¼ 0.049; Log-rank test). Times are in months. Refer Table 4.
Table 4. Survival for aneurysmal disease is significantly worse
than for occlusive disease (p[ 0.049; Log-rank test). Times are
in months
Time Total Fail Lost Function [95% Conf. int.]
Aneurysmal
0.5 21 2 0 0.9048 0.6700e0.9753
1 19 1 0 0.8571 0.6197e0.9516
2 18 1 3 0.8095 0.5689e0.9239
3 14 2 1 0.6939 0.4379e0.8507
5 11 2 0 0.5677 0.3123e0.7592
6 9 2 0 0.5046 0.2574e0.7085
12 7 0 1 0.4416 0.2067e0.6545
13 6 1 2 0.3680 0.1486e0.5920
37 3 0 2 0.3680 0.1486e0.5920
46 1 0 1 0.3680 0.1486e0.5920
Occlusive
0.5 54 3 0 0.9444 0.8376e0.9817
1 51 5 7 0.8889 0.7693e0.9485
6 39 4 7 0.8022 0.6623e0.8888
9 28 2 1 0.7236 0.5681e0.8311
12 25 2 7 0.6411 0.4768e0.7657
18 16 0 3 0.6411 0.4768e0.7657
24 13 1 2 0.5918 0.4116e0.7334
28 10 1 3 0.5326 0.3366e0.6945
37 6 0 5 0.5326 0.3366e0.6945
46 1 0 1 0.5326 0.3366e0.6945
Refer Fig. 4.
395Surgical Intervention for HIV Related Vascular Diseaseprobability of sepsis. Savoiz21 has shown that 35% of
infective complications in HIV/AIDS patients are
caused by opportunistic infections outside the range
of normal vascular prophylaxis. These require thera-
peutic antibiotic and anti-fungal treatment according
to microscopy, culture and sensitivity (MCS). In AIDS
patients we recommend a broad spectrum antibiotic
as prophylaxis and usually continue with co-
trimoxazole for six weeks, unless MCS dictates
differently. A single dose of fluconazole as prophy-
laxis against fungal infection is also routinely given
to these patients.
We had no patients on highly active antiretroviral
therapy (HAART), but in three patients, who received
HAART for a period of 3 months in the private sector,
the viral counts showed a marked reduction and there
was a significant improvement in the CD4 T-cell
counts. HAART has been shown in the literature to
be effective in patients with advanced immune sup-
pression.26 Palella et al.26 analyzed data on 1255
patients and showed a decline in mortality and
morbidity attributable to the use of more intensive
antiretroviral therapies. Multiple clinical trials have
shown viral and immunologic efficacy of the newer
HAART combinations by measuring the plasma load
of HIV RNA and CD4 T-cell counts. There is, how-
ever, concern about patient compliance and the
long-term adverse effects of the therapy. Currently ac-
cepted indications for HAART are summarized in
Table 5.
The most common side effects are haematological
toxicity, hepatotoxicity, hyperlactataemia, hyperlipid-
emia, lipodystrophy and hypersensitivity. Peri-opera-
tive use of HAART at this stage, however, is limited to
patients who require elective surgery that can be post-
poned for at least 3 months to reach the maximum
benefit of increased CD4 T-cell count and decreased
plasma viral load.
We are facing an increasing population with HIV
and who may present with HIV associated vasculop-
athy. The dilemma that faces the vascular surgeon is
when to intervene and what intervention is preferable.
At the time when we started this study there were
no clear guidelines. Although our patient numbers
at present are still relatively small, we have learnt
valuable lessons and think that we can make certain
recommendations. The peri-operative morbidity and
Table 5. Indications for HAART therapy
 Symptomatic patients in clinical WHO stage 3 or 4 Asymptomatic patients with CD4 T-cell count <200 cells/mL CD4 T-cell count¼ 200e350 cells/mL (individualised, viral
load> 100,000) Treatment should be deferred if CD4 t-cell count >350 cell/mLmortality of aneurysm repair is high with a poor
long-term survival. Aneurysm repair should be re-
served for life- and limb-threatening conditions.
Limb salvage rate is poor in patients presenting
with critical limb ischemia due to occlusive disease.
The complication rate and length of stay was also
more in patients who underwent secondary amputa-
tion after failed bypass surgery. We therefore think
that primary amputation is an option to consider,
especially in patients with additional aggravating
factors.
CD4 T-cell count is not a good predictor of outcome
and should not be used as the only criteria to deter-
mine management.
We have not employed endovascular techniques or
used HAART during this study and the future use of
these modalities may change the outcome. This is part
of an ongoing study.
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